Ropivacaine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ropivacaine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Hypotension | 32.3% |
| Nausea | 17% |
| Fetal bradycardia | 12.1% |
| Neonatal jaundice | 8.2% |
| Vomiting | 7% |
| Neonatal complication-nos | 6.6% |
| Bradycardia | 5.8% |
| Back pain | 5.2% |
| Headache | 5.1% |
| Pain | 5% |
| Paresthesia | 4.9% |
| Pruritus | 3.8% |
| Fever | 3.7% |
| Postoperative complications | 3.1% |
| Neonatal respiratory disorder | 3.1% |
| Apgar score low | 2.8% |
| Neonatal hypoglycemia | 2.8% |
| Neonatal tachypnea | 2.6% |
| Dizziness | 2.5% |
| Rigors (chills) | 2.5% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia : epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management : epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration
Medical disclaimer: Always consult a qualified healthcare professional about any medication.
Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.
Compare lab testing options near you ↗ (affiliate link)